デフォルト表紙
市場調査レポート
商品コード
1631371

進行性多巣性白質脳症治療の世界市場:業界分析、規模、シェア、成長、動向、予測(2025年~2032年)

Progressive Multifocal Leukoencephalopathy Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032


出版日
ページ情報
英文 208 Pages
納期
2~5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
進行性多巣性白質脳症治療の世界市場:業界分析、規模、シェア、成長、動向、予測(2025年~2032年)
出版日: 2025年01月09日
発行: Persistence Market Research
ページ情報: 英文 208 Pages
納期: 2~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の進行性多巣性白質脳症治療の市場規模は、2025年に9億8,340万米ドルになるとみられ、2025年~2032年の予測期間に6.5%のCAGRで拡大し、2032年には15億2,820万米ドルに達すると予測されています。

進行性多巣性白質脳症治療市場には、ジョン・カニンガムウイルス(JCV)によって引き起こされる稀でしばしば致命的なウイルス性疾患であるPMLの管理と治療を目的とした治療法と診断ソリューションが含まれます。この疾患は主に、臓器移植、化学療法、または免疫抑制剤による治療を受けている患者を含む免疫不全の個人に影響を及ぼします。この市場は、ヘルスケア提供者、専門クリニック、病院、調査機関を対象としています。成長の原動力となっているのは、免疫抑制疾患の有病率の増加、抗ウイルス療法の進歩、ヘルスケア専門家の意識の高まりです。

世界のPML治療市場を牽引する主な要因はいくつかあります。HIV/AIDSやがんなどの免疫不全状態の発生率の上昇は、市場の成長に大きく貢献しています。JCウイルスの複製を標的とする抗ウイルス薬などの開発により、PML治療の有効性と安全性が向上しています。高度な画像技術と分子診断による早期診断の重要性が高まっており、タイムリーな介入と患者の転帰の改善に役立ちます。さらに、免疫療法と遺伝子治療を探求する調査イニシアチブにより、PML治療の新たな可能性が生まれ、市場の拡大に貢献しています。

PML治療市場には、標的療法の研究開発への投資増加により、大きなチャンスが生まれています。抗ウイルス薬と免疫調節薬を統合した併用療法の導入、患者の転帰改善が期待されます。製薬会社と学術調査機関の連携により、治療の革新が促進されます。新興市場への進出と、早期診断および治療に関する啓発キャンペーンを組み合わせることで、成長への道が開かれます。さらに、個人の遺伝子プロファイルに合わせた治療法などの個別化医療の進歩は、ヘルスケアの進化する動向と一致し、市場の可能性を高めます。

当レポートでは、世界の進行性多巣性白質脳症治療市場について調査し、薬剤タイプ別、適応症別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

第3章 進行性多巣性白質脳症治療市場機会分析

第4章 市場背景

第5章 主な内容

第6章 北米の進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)

第7章 ラテンアメリカの進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)

第8章 欧州の進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)

第9章 中国を除くアジア太平洋の進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)

第10章 中東・アフリカの進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)

第11章 予測要因:関連性と影響

第12章 競合分析

  • 競合ダッシュボード
  • 企業の詳細
    • Pfizer, Inc.
    • F. Hoffman - La Roche Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Sanofi S.A.
    • Allergan plc (Actavis plc)
    • Novartis AG
    • Mylan N.V.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company

第13章 世界の進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)、地域別

第14章 世界の進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)、薬剤タイプ別

第15章 世界の進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)、適応症別

第16章 世界の進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)、流通チャネル別

第17章 世界の進行性多巣性白質脳症治療市場分析(2019年~2024年)および予測(2025年~2032年)

目次
Product Code: PMRREP15679

Persistence Market Research has recently published an extensive report on the global Progressive Multifocal Leukoencephalopathy (PML) Treatment Market. This report provides a detailed analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering deep insights into the market structure.

Key Insights:

  • PML Treatment Market Size (2025E): USD 983.4 Mn
  • Projected Market Value (2032F): USD 1528.2 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.5%

PML Treatment Market - Report Scope:

The Progressive Multifocal Leukoencephalopathy Treatment Market encompasses therapies and diagnostic solutions aimed at managing and treating PML, a rare and often fatal viral disease caused by the John Cunningham virus (JCV). The condition primarily affects immunocompromised individuals, including patients undergoing organ transplantation, chemotherapy, or treatment with immunosuppressive drugs. The market serves healthcare providers, specialty clinics, hospitals, and research institutes. Growth is driven by the increasing prevalence of immunosuppressive conditions, advancements in antiviral therapies, and heightened awareness among healthcare professionals.

Market Growth Drivers:

Several key factors drive the global PML Treatment Market. The rising incidence of immunocompromised conditions, such as HIV/AIDS and cancer, significantly contributes to market growth. Developments in antiviral drugs, such as those targeting JC virus replication, enhance the efficacy and safety of PML treatments. The growing emphasis on early diagnosis through advanced imaging techniques and molecular diagnostics aids in timely intervention and improved patient outcomes. Furthermore, research initiatives exploring immunotherapy and gene therapy create new possibilities for PML treatment, contributing to market expansion.

Market Restraints:

Despite the promising growth prospects, the PML Treatment Market faces several challenges. High treatment costs, especially for novel therapies, pose financial barriers for patients in low- and middle-income countries. Limited availability of targeted therapies and the lack of effective preventive measures hinder market growth. Additionally, the complexity of diagnosing PML and the reliance on symptomatic treatment for managing the disease contribute to challenges in addressing patient needs effectively. Addressing these issues requires collaborative efforts between healthcare providers, pharmaceutical companies, and policymakers.

Market Opportunities:

The PML Treatment Market presents significant opportunities driven by the increasing investment in research and development of targeted therapies. The introduction of combination therapies, which integrate antiviral drugs and immunomodulators, offers hope for better patient outcomes. Collaborations between pharmaceutical companies and academic research institutes foster innovation in treatment modalities. Expansion into emerging markets, coupled with awareness campaigns about early diagnosis and treatment, creates avenues for growth. Additionally, advancements in personalized medicine, such as therapies tailored to individual genetic profiles, align with evolving trends in healthcare and enhance market potential.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Progressive Multifocal Leukoencephalopathy Treatment Market globally?
  • Which therapeutic approaches and diagnostic solutions are leading in terms of adoption and efficacy?
  • How are technological advancements influencing the competitive landscape of the PML Treatment Market?
  • Who are the key players in the PML Treatment Market, and what strategies are they employing to remain competitive?
  • What are the emerging trends and future prospects in the global PML Treatment Market?

Competitive Intelligence and Business Strategy:

Leading players in the global PML Treatment Market, including pharmaceutical companies and biotech firms, focus on innovation, clinical trials, and strategic partnerships to maintain a competitive edge. These companies invest in R&D to develop antiviral agents and immunomodulatory therapies that address specific patient needs. Collaborations with research institutions and healthcare providers enhance access to advanced treatments. Emphasis on regulatory approvals, patient safety, and targeted marketing campaigns strengthens market presence and fosters growth in the evolving PML Treatment Market landscape.

Key Companies Profiled:

  • Pfizer, Inc.
  • F. Hoffman - La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Allergan plc (Actavis plc)
  • Overview
  • Novartis AG
  • Mylan N.V.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Others.

PML Treatment Market Industry Segmentation:

By Treatment Type:

  • Antiviral Therapies
  • Immunomodulatory Therapies
  • Adjunctive Therapies

By Diagnostic Approach:

  • MRI and Imaging
  • Molecular Diagnostics
  • Serological Tests

By End User:

  • Hospitals
  • Specialty Clinics
  • Research Institutes

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations
  • 1.4. Wheel of Fortune

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy

3. Progressive Multifocal Leukoencephalopathy Treatment Market Opportunity Analysis

  • 3.1. Macro-Economic Factors
  • 3.2. Opportunity Analysis

4. Market Background

  • 4.1. Market Dynamics
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Trends

5. Key Inclusions

  • 5.1. Key Regulations
  • 5.2. Pipeline Analysis

6. North America Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 6.1. Introduction
  • 6.2. Historical Market Size (US$ Mn) & Analysis By Country, 2019 - 2024
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Market Size (US$ Mn) & Forecast By Country, 2025 - 2032
  • 6.4. Historical Market Size (US$ Mn) By Drug Type, 2019 - 2024
    • 6.4.1. Anti-retroviral Therapy
    • 6.4.2. Antiviral/Anti JCV
    • 6.4.3. Other Symptomatic
  • 6.5. Market Size (US$ Mn) Forecast By Drug Type, 2025 - 2032
  • 6.6. Historical Market Size (US$ Mn) By Indication, 2019 - 2024
    • 6.6.1. HIV/AIDS
    • 6.6.2. Organ Transplantation
    • 6.6.3. Multiple Sclerosis
    • 6.6.4. Hematological Malignancies
  • 6.7. Market Size (US$ Mn) Forecast By Indication, 2025 - 2032
  • 6.8. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2019 - 2024
    • 6.8.1. Hospital Pharmacies
    • 6.8.2. Drug Stores
    • 6.8.3. Retail Pharmacies
  • 6.9. Market Size (US$ Mn) and Forecast By Distribution Channel, 2025 - 2032
  • 6.10. Market Attractiveness Analysis
    • 6.10.1. By Country
    • 6.10.2. By Drug Type
    • 6.10.3. By Indication
    • 6.10.4. By Distribution Channel
  • 6.11. Drivers and Restraints: Impact Analysis

7. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024and Forecast 2025 - 2032

  • 7.1. Introduction
  • 7.2. Historical Market Size (US$ Mn) Trends and Analysis By Country, 2019 - 2024
    • 7.2.1. Brazil
    • 7.2.2. Mexico
    • 7.2.3. Rest of Latin America
  • 7.3. Market Size (US$ Mn) & Forecast By Country, 2025 - 2032
  • 7.4. Historical Market Size (US$ Mn) By Drug Type, 2019 - 2024
    • 7.4.1. Anti-retroviral Therapy
    • 7.4.2. Antiviral/Anti JCV
    • 7.4.3. Other Symptomatic
  • 7.5. Market Size (US$ Mn) Forecast By Drug Type, 2025 - 2032
  • 7.6. Historical Market Size (US$ Mn) By Indication, 2019 - 2024
    • 7.6.1. HIV/AIDS
    • 7.6.2. Organ Transplantation
    • 7.6.3. Multiple Sclerosis
    • 7.6.4. Hematological Malignancies
  • 7.7. Market Size (US$ Mn) Forecast By Indication, 2025 - 2032
  • 7.8. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2019 - 2024
    • 7.8.1. Hospital Pharmacies
    • 7.8.2. Drug Stores
    • 7.8.3. Retail Pharmacies
  • 7.9. Market Size (US$ Mn) and Forecast By Distribution Channel, 2025 - 2032
  • 7.10. Market Attractiveness Analysis
    • 7.10.1. By Country
    • 7.10.2. By Drug Type
    • 7.10.3. By Indication
    • 7.10.4. By Distribution Channel
  • 7.11. Drivers and Restraints: Impact Analysis

8. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024and Forecast 2025 - 2032

  • 8.1. Introduction
  • 8.2. Regional Trends
  • 8.3. Historical Market Size (US$ Mn) and Trend Analysis By Country, 2019 - 2024
    • 8.3.1. Germany
    • 8.3.2. U.K.
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Russia
    • 8.3.7. Rest of Europe
  • 8.4. Market Size (US$ Mn) & Forecast By Country, 2025 - 2032
  • 8.5. Historical Market Size (US$ Mn) By Drug Type, 2019 - 2024
    • 8.5.1. Anti-retroviral Therapy
    • 8.5.2. Antiviral/Anti JCV
    • 8.5.3. Other Symptomatic
  • 8.6. Market Size (US$ Mn) Forecast By Drug Type, 2025 - 2032
  • 8.7. Historical Market Size (US$ Mn) By Indication, 2019 - 2024
    • 8.7.1. HIV/AIDS
    • 8.7.2. Organ Transplantation
    • 8.7.3. Multiple Sclerosis
    • 8.7.4. Hematological Malignancies
  • 8.8. Market Size (US$ Mn) Forecast By Indication, 2025 - 2032
  • 8.9. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2019 - 2024
    • 8.9.1. Hospital Pharmacies
    • 8.9.2. Drug Stores
    • 8.9.3. Retail Pharmacies
  • 8.10. Market Size (US$ Mn) and Forecast By Distribution Channel, 2025 - 2032
  • 8.11. Market Attractiveness Analysis
    • 8.11.1. By Country
    • 8.11.2. By Drug Type
    • 8.11.3. By Indication
    • 8.11.4. By Distribution Channel
  • 8.12. Drivers and Restraints: Impact Analysis

9. Asia Pacific Excluding China Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 9.1. Introduction
  • 9.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019 - 2024
    • 9.2.1. China
    • 9.2.2. India
    • 9.2.3. Australia
    • 9.2.4. Japan
    • 9.2.5. ASEAN
    • 9.2.6. Rest of Asia Pacific
  • 9.3. Market Size (US$ Mn) & Forecast By Country, 2025 - 2032
  • 9.4. Historical Market Size (US$ Mn) By Drug Type, 2019 - 2024
    • 9.4.1. Anti-retroviral Therapy
    • 9.4.2. Antiviral/Anti JCV
    • 9.4.3. Other Symptomatic
  • 9.5. Market Size (US$ Mn) Forecast By Drug Type, 2025 - 2032
  • 9.6. Historical Market Size (US$ Mn) By Indication, 2019 - 2024
    • 9.6.1. HIV/AIDS
    • 9.6.2. Organ Transplantation
    • 9.6.3. Multiple Sclerosis
    • 9.6.4. Hematological Malignancies
  • 9.7. Market Size (US$ Mn) Forecast By Indication, 2025 - 2032
  • 9.8. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2019 - 2024
    • 9.8.1. Hospital Pharmacies
    • 9.8.2. Drug Stores
    • 9.8.3. Retail Pharmacies
  • 9.9. Market Size (US$ Mn) and Forecast By Distribution Channel, 2025 - 2032
  • 9.10. Market Attractiveness Analysis
    • 9.10.1. By Country
    • 9.10.2. By Drug Type
    • 9.10.3. By Indication
    • 9.10.4. By Distribution Channel
  • 9.11. Drivers and Restraints: Impact Analysis

10. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024and Forecast 2025 - 2032

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) and Trend Analysis By Country, 2019 - 2024
    • 10.2.1. GCC Countries
    • 10.2.2. South Africa
    • 10.2.3. Rest of MEA
  • 10.3. Market Size (US$ Mn) & Forecast By Country, 2025 - 2032
  • 10.4. Historical Market Size (US$ Mn) By Drug Type, 2019 - 2024
    • 10.4.1. Anti-retroviral Therapy
    • 10.4.2. Antiviral/Anti JCV
    • 10.4.3. Other Symptomatic
  • 10.5. Market Size (US$ Mn) Forecast By Drug Type, 2025 - 2032
  • 10.6. Historical Market Size (US$ Mn) By Indication, 2019 - 2024
    • 10.6.1. HIV/AIDS
    • 10.6.2. Organ Transplantation
    • 10.6.3. Multiple Sclerosis
    • 10.6.4. Hematological Malignancies
  • 10.7. Market Size (US$ Mn) Forecast By Indication, 2025 - 2032
  • 10.8. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2019 - 2024
    • 10.8.1. Hospital Pharmacies
    • 10.8.2. Drug Stores
    • 10.8.3. Retail Pharmacies
  • 10.9. Market Size (US$ Mn) and Forecast By Distribution Channel, 2025 - 2032
  • 10.10. Market Attractiveness Analysis
    • 10.10.1. By Country
    • 10.10.2. By Drug Type
    • 10.10.3. By Indication
    • 10.10.4. By Distribution Channel
  • 10.11. Drivers and Restraints: Impact Analysis

11. Forecast Factors: Relevance and Impact

12. Competition Analysis

  • 12.1. Competition Dashboard
  • 12.2. Company Deep Dive
    • 12.2.1. Pfizer, Inc.
      • 12.2.1.1. Overview
      • 12.2.1.2. Product and Application Portfolio
      • 12.2.1.3. Production Footprint
      • 12.2.1.4. Sales Footprint
      • 12.2.1.5. Channel Footprint
      • 12.2.1.6. Strategy
        • 12.2.1.6.1. Marketing Strategy
        • 12.2.1.6.2. Product Strategy
        • 12.2.1.6.3. Channel Strategy
    • 12.2.2. F. Hoffman - La Roche Ltd.
      • 12.2.2.1. Overview
      • 12.2.2.2. Product and Application Portfolio
      • 12.2.2.3. Production Footprint
      • 12.2.2.4. Sales Footprint
      • 12.2.2.5. Channel Footprint
      • 12.2.2.6. Strategy
        • 12.2.2.6.1. Marketing Strategy
        • 12.2.2.6.2. Product Strategy
        • 12.2.2.6.3. Channel Strategy
    • 12.2.3. Gilead Sciences, Inc.
      • 12.2.3.1. Overview
      • 12.2.3.2. Product and Application Portfolio
      • 12.2.3.3. Production Footprint
      • 12.2.3.4. Sales Footprint
      • 12.2.3.5. Channel Footprint
      • 12.2.3.6. Strategy
        • 12.2.3.6.1. Marketing Strategy
        • 12.2.3.6.2. Product Strategy
        • 12.2.3.6.3. Channel Strategy
    • 12.2.4. GlaxoSmithKline plc
      • 12.2.4.1. Overview
      • 12.2.4.2. Product and Application Portfolio
      • 12.2.4.3. Production Footprint
      • 12.2.4.4. Sales Footprint
      • 12.2.4.5. Channel Footprint
      • 12.2.4.6. Strategy
        • 12.2.4.6.1. Marketing Strategy
        • 12.2.4.6.2. Product Strategy
        • 12.2.4.6.3. Channel Strategy
    • 12.2.5. Sanofi S.A.
      • 12.2.5.1. Overview
      • 12.2.5.2. Product and Application Portfolio
      • 12.2.5.3. Production Footprint
      • 12.2.5.4. Sales Footprint
      • 12.2.5.5. Channel Footprint
      • 12.2.5.6. Strategy
        • 12.2.5.6.1. Marketing Strategy
        • 12.2.5.6.2. Product Strategy
        • 12.2.5.6.3. Channel Strategy
    • 12.2.6. Allergan plc (Actavis plc)
      • 12.2.6.1. Overview
      • 12.2.6.2. Product and Application Portfolio
      • 12.2.6.3. Production Footprint
      • 12.2.6.4. Sales Footprint
      • 12.2.6.5. Channel Footprint
      • 12.2.6.6. Strategy
        • 12.2.6.6.1. Marketing Strategy
        • 12.2.6.6.2. Product Strategy
        • 12.2.6.6.3. Channel Strategy
    • 12.2.7. Novartis AG
      • 12.2.7.1. Overview
      • 12.2.7.2. Product and Application Portfolio
      • 12.2.7.3. Production Footprint
      • 12.2.7.4. Sales Footprint
      • 12.2.7.5. Channel Footprint
      • 12.2.7.6. Strategy
        • 12.2.7.6.1. Marketing Strategy
        • 12.2.7.6.2. Product Strategy
        • 12.2.7.6.3. Channel Strategy
    • 12.2.8. Mylan N.V.
      • 12.2.8.1. Overview
      • 12.2.8.2. Product and Application Portfolio
      • 12.2.8.3. Production Footprint
      • 12.2.8.4. Sales Footprint
      • 12.2.8.5. Channel Footprint
      • 12.2.8.6. Strategy
        • 12.2.8.6.1. Marketing Strategy
        • 12.2.8.6.2. Product Strategy
        • 12.2.8.6.3. Channel Strategy
    • 12.2.9. AbbVie Inc.
      • 12.2.9.1. Overview
      • 12.2.9.2. Product and Application Portfolio
      • 12.2.9.3. Production Footprint
      • 12.2.9.4. Sales Footprint
      • 12.2.9.5. Channel Footprint
      • 12.2.9.6. Strategy
        • 12.2.9.6.1. Marketing Strategy
        • 12.2.9.6.2. Product Strategy
        • 12.2.9.6.3. Channel Strategy
    • 12.2.10. Bristol-Myers Squibb Company
      • 12.2.10.1. Overview
      • 12.2.10.2. Product and Application Portfolio
      • 12.2.10.3. Production Footprint
      • 12.2.10.4. Sales Footprint
      • 12.2.10.5. Channel Footprint
      • 12.2.10.6. Strategy
        • 12.2.10.6.1. Marketing Strategy
        • 12.2.10.6.2. Product Strategy
        • 12.2.10.6.3. Channel Strategy

13. Global Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024and Forecast 2025 - 2032, By Region

  • 13.1. Introduction/Key Findings
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2019 - 2024
  • 13.3. Market Size (US$ Mn) Forecast By Region, 2025 - 2032
    • 13.3.1. North America
    • 13.3.2. Latin America
    • 13.3.3. Europe
    • 13.3.4. Asia Pacific
    • 13.3.5. Middle East & Africa
  • 13.4. Market Attractiveness Analysis By Region

14. Global Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024and Forecast 2025 - 2032, By Drug Type

  • 14.1. Introduction/Key Findings
  • 14.2. Historical Market Size (US$ Mn) By Drug Type, 2019 - 2024
    • 14.2.1. Anti-retroviral Therapy
    • 14.2.2. Antiviral/Anti JCV
    • 14.2.3. Other Symptomatic
  • 14.3. Market Size (US$ Mn) Forecast By Drug Type, 2025 - 2032
  • 14.4. Market Attractiveness Analysis By Drug Type

15. Global Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024and Forecast 2025 - 2032, By Indication

  • 15.1. Introduction/Key Findings
  • 15.2. Historical Market Size (US$ Mn) By Drug Type, 2019 - 2024
    • 15.2.1. HIV/AIDS
    • 15.2.2. Organ Transplantation
    • 15.2.3. Multiple Sclerosis
    • 15.2.4. Hematological Malignancies
  • 15.3. Market Size (US$ Mn) Forecast By Indication, 2025 - 2032
  • 15.4. Market Attractiveness Analysis By Indication

16. Global Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024and Forecast 2025 - 2032, By Distribution Channel

  • 16.1. Introduction/Key Findings
  • 16.2. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2019 - 2024
    • 16.2.1. Hospital Pharmacies
    • 16.2.2. Drug Stores
    • 16.2.3. Retail Pharmacies
  • 16.3. Market Size (US$ Mn) and Forecast By Distribution Channel, 2025 - 2032
  • 16.4. Market Attractiveness Analysis By Distribution Channel

17. Global Progressive Multifocal Leukoencephalopathy Treatment Market Analysis 2019 - 2024and Forecast 2025 - 2032

  • 17.1. Market Value Share Analysis By All Segment
  • 17.2. Y-o-Y Growth Analysis By All Segment
  • 17.3. Absolute $ Opportunity
  • 17.4 Research Methodology